WilmerHale Advises Beam Therapeutics on $500 Million Underwritten Offering

WilmerHale Advises Beam Therapeutics on $500 Million Underwritten Offering

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On March 10, 2025, Beam Therapeutics Inc., a biotechnology company establishing the leading, fully integrated platform for precision genetic medicines, anchored by its proprietary base editing technology, announced the pricing of its underwritten registered direct offering of 16,151,686 shares of its common stock and pre-funded warrants to purchase 1,404,988 shares of its common stock. The aggregate gross proceeds to Beam were $500 million, before deducting underwriting discounts and commissions and other offering expenses payable by Beam. 

The WilmerHale team representing Beam consisted of Cynthia Mazareas, Molly Fox, Erin Bruynell Gallagher and Emily Ivers, with assistance from Meghan Walsh, Ben Kelsey, Simona Altshuler, Bruce Manheim, Tim Silva, Annaka Merrick, Heidi Treiber and Cindy Sullivan. 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel